BI-1206

• Target :

  Immunology/Inflammation related|||Others

• Related Pathways :

  Immunology/Inflammation|||Others

• Bioactivity :

  BI-1206 is a recombinant antagonistic human monoclonal antibody targeting Fc?RIIB (CD32B) . It inhibits CD20 internalization induced by Rituximab, whether used alone or in combination with drugs such as Ibrutinib, Venetoclax, and CHOP. BI-1206 can enhance or restore the activity of Rituximab or other anti-CD20 monoclonal antibodies and demonstrates cytolytic activity against malignant B cells. BI-1206 is applicable in research on cancers such as mantle cell lymphoma (MCL) .

• Shipping Conditions :

  Cool pack

• Storage Temperature :

  -20°C